Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type of Patient: Outpatient
Informed Consent: A signed and dated written informed consent prior to study participation
Age: Subjects 40 years of age or older at Visit 1
Gender: Male or female subjects.
COPD diagnosis: As defined by the American Thoracic Society/European Respiratory Society (ATS/ERS)
Severity of disease: A pre- and post-salbutamol FEV1/FVC ratio of \<0.70 and a pre- and post-salbutamol FEV1 of ≤ 70% of predicted normal values at Visit 1
Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years at Visit 1
Female subject of non child-bearing potential OR a female subject of child bearing potential, with a negative pregnancy test at screening, and agreeing to consistently and correctly use one of the acceptable contraceptive methods
You may not be if
Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
Asthma: A current diagnosis of asthma
Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions.
Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \< 5 years prior to Visit 1
Contraindications: A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1
Screening Labs: Significantly abnormal finding from clinical chemistry or hematology tests at Visit 1 as determined by the study investigator.
Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period required prior to spirometry testing at each study visit and at each spirometry test performed at home.
Medications Prior to Screening: Use of the prohibited medications according to defined time intervals prior to Visit 1
Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤ 12 hours per day) is not exclusionary.
Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol, ipratropium bromide) via nebulized therapy
Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete a questionnaire
Clareo Health | Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
